1	19 if felbamate be use as a concomitant aed subject must be on felbamate for at least 2 year with a stable dose for 2 month or no less than 49 day prior to visit 1 they must not have a history of white blood cell wbc count below 2500/?l 2.50 1e+09/l platelet below 100,000 liver function test|felbamate[6,15]|||||||||C0060135|24812|24812|felbamate
1	19 if felbamate be use as a concomitant aed subject must be on felbamate for at least 2 year with a stable dose for 2 month or no less than 49 day prior to visit 1 they must not have a history of white blood cell wbc count below 2500/?l 2.50 1e+09/l platelet below 100,000 liver function test|felbamate[63,72]|||||||2 month[116,123]||C0060135|24812|24812|felbamate
2	lfts above 3 time the upper limit of normal uln or other indication of hepatic or bone marrow dysfunction while receive felbamate if subject receive felbamate in the past it must have be discontinue 2 month or no less than 49 day prior to visit 1|felbamate[413,422]|||||||||C0060135|24812|24812|felbamate
2	lfts above 3 time the upper limit of normal uln or other indication of hepatic or bone marrow dysfunction while receive felbamate if subject receive felbamate in the past it must have be discontinue 2 month or no less than 49 day prior to visit 1|felbamate[442,451]|||||||2 month[492,499]||C0060135|24812|24812|felbamate
